Notice of AGM 2012

Notice is hereby given that the Annual General Meeting of Cyprotex PLC (the "Company") will be held at The ENT Room, The Royal Society of Medicine,1 Wimpole Street, London on 17 July 2012 at 10.00 am.

Download Notice of Annual General Meeting

For further information:

Cyprotex PLC
Tel: +44 (0) 1625 505 100
Dr Anthony Baxter, Chief Executive Officer
John Dootson, Chief Financial Officer
Mark Warburton, Chief Operating Officer and Legal Counsel
ir@cyprotex.com
www.cyprotex.com

Singer Capital Markets Limited (broker to Cyprotex)
Tel: +44 (0)20 7496 3000
Shaun Dobson
shaun.dobson@singercm.com
Claes Spang
claes.spang@singercm.com

Financial Dynamics
Tel: +44 (0) 20 7831 3113
Ben Brewerton
Ben Atwell
Mo Noonan
cyprotex@fd.com
www.fd.com

Notes to Editors:

Cyprotex PLC

Cyprotex is the world's largest contract research organisation (CRO) specialising in ADME Tox, which is the analysis of the Absorption, Distribution, Metabolism, Excretion, and Toxicity properties of potential drugs, cosmetics, and agrochemicals. It is the only company in the world with in-house capabilities for both in vitro (test tube) and in silico (computer modelling) ADME Tox. Cyprotex was founded in 1999 and listed on the AIM in 2002. It has laboratories in Macclesfield, Cheshire, UK (near Manchester), and Watertown, Massachusetts, USA (near Boston), making it one of only three ADME Tox CROs with international operations.